TCI uses cookies to personalize and improve your user experience. By continuing on our website, you accept the use of cookies. You can change or update your cookiesettings at any time.
Maintenance Notice (12:30 AM - 4:00 AM June 8, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
(R,R)-DIPAMP
[=(R,R)-1,2-Bis[(2-methoxyphenyl)phenylphosphino]ethane] (1a) (*This product is discontinued.)
B3036
(S,S)-DIPAMP
[=(S,S)-1,2-Bis[(2-methoxyphenyl)phenylphosphino]ethane] (1b) (*This product is discontinued.)
Compound 1 are P-chiral ligands developed by Knowles et al. This compound 1
forms a stable complex with rhodium, and the complex has been used as a catalyst for an asymmetric hydrogenation
reaction. Particularly, the asymmetric hydrogenation reaction of α-acetylamino cinnamic acid derivative 2
is well known, and it provides L-amino acid derivative 3 with high optical purity. When this compound 3
is de-protected, L-DOPA, which is used for the treatment of Parkinsonism, can be obtained. Knowles won the Nobel Prize
in Chemistry for his achievement of developing this asymmetric synthesis of L-DOPA in 2001.
References
1) Asymmetric hydrogenation with a complex of Rh and a chiral bisphosphine
The prices are subject to change without notice. Please confirm the newest price by our online
catalog before placing an order.
In addition, sales products changes with areas. Please understand that a product is not available when the product
details page is not displayed.
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.